FindTrial
Sign In

A systematic review of the efficacy of "rice-derived glucosylceramide" in maintaining immune function in healthy adults.

A systematic review of the efficacy of "rice-derived glucosylceramide" in maintaining immune function in healthy adults. - A systematic review of the efficacy of "rice-derived glucosylceramide" in maintaining immune function in healthy adults.

Status
Active, not recruiting
Phases
Unknown
Study type
Unknown
Source
JPRN
Registry ID
JPRN-UMIN000060525
Enrollment
Unknown
Registered
2026-01-30
Start date
2026-01-23
Completion date
Unknown
Last updated
2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Healthy adults

Interventions

None listed

Sponsors

Oryza Oil and Fat Chemical Co., Ltd.
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: P-Participant: Participant The subjects were healthy adults (those who are not suffering from any diseases, excluding those under 18 years old, pregnant women, and lactating women) I-intervention: Intervention (food) characteristics Continuous intake of rice-derived glucosylceramide, Unlimited dosage forms, period and follow-up period. C-Comparison: Comparison Placebo (The placebo's formulation is not specified) O-Outcome: Outcome The primary outcome: - Immune markers (monocytes) - Immune markers (Dendritic cell; DC) - Whether overall subjective symptoms related to physical condition are maintained at a mild level. - Whether subjective symptoms in specific body parts related to physical condition are maintained at a mild level. The secondary outcome: Do not set S-Study design: Study design Randomized parallel group controlled trials, randomized crossover trials, quasi-randomized parallel group controlled trials, quasi-randomized crossover trials, non-randomized parallel group controlled trials, non-randomized crossover trials or open trial

Exclusion criteria

Exclusion criteria: The literature which does not meet PICOS, such as conference abstracts (conference proceedings) that are not original articles will be excluded.

Design outcomes

Primary

MeasureTime frame
- Immune markers (monocytes) - Immune markers (Dendritic cell; DC) - Whether overall subjective symptoms related to physical condition are maintained at a mild level. - Whether subjective symptoms in specific body parts related to physical condition are maintained at a mild level.—

Countries

Japan

Contacts

Public ContactMarina Hirano

Oryza Oil and Fat Chemical Co., Ltd. Planning & Solution Development Department Section

kaihatsu@mri.biglobe.ne.jp0586-86-5141

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026